ID: MRFR/HC/6649-HCR | February 2021 | Region: Global | 90 pages
The preimplantation genetic testing market held a valuation of USD 375.8 million in 2018 and is projected to register a CAGR of around 10.2% over the forecast period.
Preimplantation genetic testing is a wide term, which is used to describe the genetic analysis of cells of an embryo, and the outcome is used for analysis and guide, which embryos should transfer to the uterus.
Also, nowadays, preimplantation genetic testing has become much more common in North America and Europe due to innovation in genetic technology like NGS and FISH over the traditional genetic technology
Population suffering from disorders related to the gene is expected to drive the preimplantation genetic testing market. Thus, awareness of people about genetic disorders helps to avoid the risk of having babies with certain genetic disorders.
March of Dimes, a voluntary health group of the US stated about 60%,34% and 6% of babies with serious birth defects were born in developing countries, middle-income countries and rich countries respectively.
Additionally,3.3 million children less than five years die each year from serious birth defects worldwide. But genetic medical services and effective interventions, especially in developing countries, could reduce disability and mortality by up to 70%.
Hence raising awareness of preimplantation genetic testing drive the global preimplantation genetic testing market.
The global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.
The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS). By type, it is divided into chromosomal abnormalities, X-linked diseases, embryo testing, aneuploidy screening, LA typing, and others. By Application it is segmented into embryo HLA typing for stem cell therapy prognosis, late-onset genetic disorders, inherited the genetic disease and others. By technology, the market is divided into
next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, and single-nucleotide polymorphism. By product and service, it is divided into reagents and consumables, instruments and software and services and lastly by end user the market is divided into maternity centers & fertility clinics, hospitals, diagnostic labs and research laboratories & academic institutes
Preimplantation genetic diagnosis (PGD) segment is expected to hold the largest market share of the preimplantation genetic testing market owing to rising awareness patients as well as healthcare professionals about genetic testing. Also, preimplantation genetic screening (PGS) segment is anticipated profitable growth during the forecast period as it reduces the miscarriage risk, increase the possibility of a healthy pregnancy in all age groups
By technology, the next-generation sequencing segment also expected to hold a large share as its cost is reduced and its capability to detect mosaicism.
By product & service, the reagents and consumables segment expected to hold the largest market share as there is continuous declination infertility of female due to the increase in maternity age.
In the current scope of the study, the segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The preimplantation genetic testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Preimplantation Genetic Testing market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Preimplantation Genetic Testing Market Share (%), by Region, 2017
Sources: MRFR Analysis
March of Dimes, the US voluntary health group stated that 7.9 million children are born with a serious birth defect of genetic or partially genetic origin, that is, 6% of total births in a year worldwide. This estimation is drawn from a study of 193 countries. As the genetic defects are growing, there is an increase in awareness about preimplantation genetic testing in population worldwide.
US Department of Health & Human Services stated that Infertility is very common. Thus, out of 100 couples in the US, about 12 to 13 of them have trouble getting pregnant. About 10 in 100 (6.1 million) women in the US aged 15 to 44 have a problem in getting pregnant or staying pregnant. Hence the prevalence of infertility causes an increase in the number of IVF procedures in the US, which is expected to drive the market.
As the maternal age in Europe is increasing complications regarding childbirth along with the threat of abnormalities in chromosomes is also rising. This leads to an increase in preimplantation genetic testing for baby birth with normal genes.
The rising participation of market players is also strongly impacting the growth of the Asia-Pacific Preimplantation Genetic Testing market.
On the other hand, the Middle East and Africa held the least share in the global market due to the low economic development, especially within the African region.
Global Preimplantation Genetic Testing Market, by Procedure
Global Preimplantation Genetic Testing Market, by Type
Preimplantation Genetic Testing Market, by Application
Preimplantation Genetic Testing Market, by Technology
Preimplantation Genetic Testing Market, by Product and Service
Global Preimplantation Genetic Testing Market, by End User
Global Preimplantation Genetic Testing Market, by Region
|Market Size||2025: Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Procedure, Type, Application, Technology, Product and Service|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science Ltd|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||Rising awareness regarding its benefits|
Frequently Asked Questions (FAQ) :
The preimplantation genetic testing market would register a CAGR of 10.2% during the forecast period of 2019 to 2025.
The preimplantation genetic testing market valuation in 2018 was USD 375.8 million.
Rising awareness regarding its benefits would increase the preimplantation genetic testing market volume.
The Preimplantation genetic diagnosis (PGD) segment would lead to the preimplantation genetic testing market.
The next-generation sequencing has the upper hand in the preimplantation genetic testing market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.